RIGL - Rigel Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.515
-0.025 (-0.551%)
As of 3:12PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.540
Open4.590
Bid4.510 x 1700
Ask4.520 x 1400
Day's Range4.380 - 4.710
52 Week Range1.940 - 4.710
Volume1,156,374
Avg. Volume1,380,293
Market Cap661.407M
Beta1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.589
Earnings DateMar 5, 2018 - Mar 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.83
Trade prices are not sourced from all markets
  • 3 Small-Cap Biotech Stocks With Major Catalysts in 2018
    Motley Fool17 days ago

    3 Small-Cap Biotech Stocks With Major Catalysts in 2018

    Good news this year could make these small biotech stocks bigger.

  • PR Newswire18 days ago

    Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Jan. 5, 2018 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL) today announced that on December 23, 2017 and January 2, 2018 the Compensation Committee of Rigel's Board of Directors approved the grants of inducement stock options to purchase an aggregate of 200,000 shares of common stock to twelve new employees. Rigel granted stock options to purchase shares of Rigel's common stock to (i) nine of the employees with an exercise price of $3.49 per share, the closing price of Rigel's common stock on December 22, 2017, the first trading date prior to December 23, 2017, the effective date of such grants and (ii) three of the employees with an exercise price of $3.88 per share, the closing price of Rigel's common stock on December 29, 2017, the first trading date prior to January 2, 2018, the effective date of such grants.

  • Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
    PR Newswire19 days ago

    Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 4, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present an update on its product pipeline and a financial overview at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 10, 2018, at 1:30pm PST (see webcast details below). Rigel's presentation will include a review of the company's New Drug Application (NDA) for fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in adult patients with immune thrombocytopenia (ITP). The FDA has confirmed that it does not plan to convene an Oncology Drugs Advisory Committee (ODAC) meeting to discuss the NDA.  The action date for the FDA to complete its review is April 17, 2018 under the Prescription Drug User Fee Act (PDUFA).

  • Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : January 1, 2018
    Capital Cube22 days ago

    Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : January 1, 2018

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Rigel Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • The Wall Street Journallast month

    Stocks to Watch: CSX, Hess, Adobe, Costco, Aclaris Therapeutics

    Companies with shares expected to trade actively in Friday's session include CSX, Hess, Adobe Systems, Costco and Aclaris Therapeutics.

  • Rigel Announces Departure of Chief Financial Officer
    PR Newswirelast month

    Rigel Announces Departure of Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Dec. 15, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced the resignation of Ryan Maynard, executive vice president and chief financial officer, effective December 31, 2017. "On behalf of the entire company, I want to thank Ryan for his significant contributions during his sixteen years at Rigel.

  • PR Newswire2 months ago

    Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 8, 2017 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL) today announced that on December 4, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 60,000 shares of common stock to one new employee. This award was granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Rigel granted stock options to purchase shares of Rigel's common stock to one employee with an exercise price of $4.09 per share, the closing price of Rigel's common stock on December 1, 2017, the first trading date prior to December 4, 2017, the effective date of such grant.

  • Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
    PR Newswire2 months ago

    Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif. , Dec. 8, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program ...

  • Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options

    Rigel Pharmaceuticals (RIGL) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : December 6, 2017
    Capital Cube2 months ago

    Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : December 6, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Rigel Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Rigel Pharmaceuticals, Inc. : December 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Rigel Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to RIGL-US. Comparing the performance and risk of Rigel Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
    Capital Cube2 months ago

    Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017

    Categories: Yahoo FinanceGet free summary analysis Rigel Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Rigel Pharmaceuticals, Inc. – Chemocentryx, Inc., Infinity Pharmaceuticals, Inc., Innoviva, Inc., Windtree Therapeutics, Inc., Aradigm Corporation, Mylan N.V., Astrazeneca PLC Sponsored ADR, Acura Pharmaceuticals, Inc., Amgen Inc. and ... Read more (Read more...)

  • Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire2 months ago

    Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Nov. 17, 2017 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL) today announced that on November 7, 2017 and November 13, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 278,500 shares of common stock to twelve new employees. Rigel granted stock options to purchase shares of Rigel's common stock to (i) eleven of the employees with an exercise price of $3.79 per share, the closing price of Rigel's common stock on November 6, 2017, the first trading date prior to November 7, 2017, the effective date of such grants and (ii) one employee with an exercise price of $3.85 per share, the closing price of Rigel's common stock on November 10, 2017, the first trading date prior to November 13, 2017, the effective date of such grant.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RIGL earnings conference call or presentation 7-Nov-17 10:00pm GMT

    Q3 2017 Rigel Pharmaceuticals Inc Earnings Call

  • Associated Press3 months ago

    Rigel reports 3Q loss

    The South San Francisco, California-based company said it had a loss of 14 cents per share. The drug developer posted revenue of $900,000 in the period. In the final minutes of trading on Tuesday, the ...

  • Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
    PR Newswire3 months ago

    Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL) today announced the closing of its previously announced underwritten public offering of 20,815,000 ...

  • ACCESSWIRE3 months ago

    Rigel Pharmaceuticals, Fostamatinib Clinical Trials and Pipeline Review

    NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher
    Zacks4 months ago

    Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher

    Rigel Pharmaceuticals (RIGL) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.

  • Rigel Announces Pricing Of Public Offering Of Common Stock
    PR Newswire4 months ago

    Rigel Announces Pricing Of Public Offering Of Common Stock

    SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL), today announced the pricing of its previously announced underwritten public offering of 18,100,000 ...

  • 5 Top Stocks for October
    Motley Fool4 months ago

    5 Top Stocks for October

    Looking for a few great stocks to buy this month? Here are five top opportunities for you to consider.

  • Here's Why Rigel Pharmaceuticals, Inc. Reversed Course Today
    Motley Fool4 months ago

    Here's Why Rigel Pharmaceuticals, Inc. Reversed Course Today

    It looks like the share offering announced yesterday won't sting as bad as expected.

  • Rigel Announces Proposed Public Offering Of Common Stock
    PR Newswire4 months ago

    Rigel Announces Proposed Public Offering Of Common Stock

    SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it intends to offer and sell up to $40,000,000 of shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional $6,000,000 of shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • TheStreet.com4 months ago

    Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

    Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: Catabasis Pharmaceuticals and Rigel Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 3, 2017 / Shares of Catabasis surged on Monday after announcing this past Friday that it would be presenting data on its investigational oral small molecule Edasalonexent ...